NCT04418167

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended Phase 1 Last updated 3 September 2025

What this trial tests

Phase 1 trial testing JSI-1187 in Solid Tumors in 71 participants. Suspended.

Timeline

18 June 2020

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	JS InnoPharm, LLC
Phase	Phase 1
Status	Suspended
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	71
Start date	18 June 2020
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	7 locations across United States

Drugs / interventions tested

• JSI-1187 — full drug profile →
• Dabrafenib (dabrafenib) — full drug profile →

Conditions studied

• Solid Tumors — all drugs for Solid Tumors →

Sponsor

JS InnoPharm, LLC — full company profile →

Who can join

18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.
   Yin G, Huang J, Petela J, Jiang H, et al · · 2023 · cited 50× · PMID 37221195 · DOI 10.1038/s41392-023-01441-4
2. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup.
   Xie M, Xu X, Fan Y. · · 2021 · cited 46× · PMID 34012925 · DOI 10.3389/fonc.2021.672612
3. Natural products targeting the MAPK-signaling pathway in cancer: overview.
   Shi A, Liu L, Li S, Qi B. · · 2024 · cited 40× · PMID 38193944 · DOI 10.1007/s00432-023-05572-7
4. Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors.
   Indini A, Rijavec E, Ghidini M, Cortellini A, et al · · 2021 · cited 37× · PMID 34064352 · DOI 10.3390/pharmaceutics13050653
5. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.
   Avery TY, Köhler N, Zeiser R, Brummer T, et al · · 2022 · cited 31× · PMID 35965494 · DOI 10.3389/fonc.2022.931774
6. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
   Rizzo A, Federico AD, Ricci AD, Frega G, et al · · 2020 · cited 29× · PMID 33356500 · DOI 10.1177/1073274820983013
7. Targeting Mutant <i>KRAS</i> in Pancreatic Cancer: Futile or Promising?
   Nollmann FI, Ruess DA. · · 2020 · cited 27× · PMID 32796566 · DOI 10.3390/biomedicines8080281
8. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
   Gupta A, Kurzrock R, Adashek JJ. · · 2023 · cited 19× · PMID 36900367 · DOI 10.3390/cancers15051578